A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Phase 1 Active not recruiting 204 enrolled Latigo Biotherapeutics

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants

Timeline

Start: 2023-10-17
Primary completion: 2026-09
Completion: 2026-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LTG-001	Unknown	—	Oral

Indications

No indication recorded.